USAID DISCOVER-Health

12- Multi-Month Dispensation (12 MMD) Implementation Update

Adamson Paxon NDHLOVU, BScHB, MBChB, PgD, MSc

John Snow Inc., Lusaka, Zambia

CQUIN 8th Annual Meeting | December 9-13, 2024 – Johannesburg, South Africa

Background

6 MMD

- WHO recommended for clinically-stable recipients of care
- Several studies in Sub-Saharan Africa demonstrated the benefits and that 6-MMD is non-inferior to 3-MMD
- 6-MMD generally considered **standard of care**, with growing interest for longer ARV dispensing intervals

12 MMD

- Rationale: USAID Project piloted the 12 MMD as part of interventions to **mitigate observed high treatment interruption** in some districts

12 MMD Implementation Building Blocks

Model Type	Facility Individual Model
Name of Model	12 Multi-month Dispensation (12-MMD)
Settings	Urban/rural
Number of RoCs in a group	Unlimited
Eligibility Criteria	Stable Clients, likely to travel out of town within 1 year
	Valid viral load result within one month
Clinical Reviews/Viral Load Collection	
Who	Physician, Clinical Officer, HIV Nurse Practitioner, Nurse
When	Every 12 months
Where	Health facility
ART refill	
Who	Pharmacist, CO, HNP, Nurse, CHW, CHA
When	Every 12 months
Where	Facility and community – delivery by CHW (case-manager)

Implementation Pathway



Tools Used	
Overall	12 MMD Protocol
Client Education	Capacity building curriculum for CBVs
Registration and Enrolment	Standard SmartCare (SC) forms revised for 12 MMD
6-month Adherence Call	Standard SC adherence form revised for 12MMD
12-month Follow Up	Standard SC Clinical Follow Up Forms

12 MMD Data Collection Tool

Data Collection Tool

District	Facility	Participant ID	Sex	Age	Patient Status_End point	Most recent VL Result (Enter actual value)	Date of the most recent VL result (DD/MM/YYYY)	VL within past 12 months	Virological status_End point	VLC	Age Band	Missed at least a dose	Hub
Chibombo	mwanjuni	10012902406	Female	38	Active	0	8/16/2024	Yes	Supressed	1	35-39	No	Chibombo Hub
Chibombo	mwanjuni	10103701023	Female	53	Active	0	3/23/2024	Yes	Supressed	1	50+	No	Chibombo Hub
Chibombo	mwanjuni	10012902325	Male	38	Active	0	4/10/2024	Yes	Supressed	1	35-39	No	Chibombo Hub
Chibombo	mwanjuni	10103701854	Female	66	Active	0	7/18/2024	Yes	Supressed	1	50+	No	Chibombo Hub
Chibombo	mwanjuni	10012902537	Female	19	Active	0	8/12/2024	Yes	Supressed	1	15-19	No	Chibombo Hub
Chibombo	mwanjuni	10012902379	Female	32	Active	0	7/18/2024	Yes	Supressed	1	30-34	No	Chibombo Hub
Chibombo	mwanjuni	10103701389	Female	34	Active	0	4/2/2024	Yes	Supressed	1	30-34	No	Chibombo Hub
Chibombo	mwanjuni	10103701539	Female	25	Active	27	5/20/2024	Yes	Supressed	1	25-29	No	Chibombo Hub
Chibombo	mwanjuni	10103702026	Male	19	Active	0	3/19/2024	Yes	Supressed	1	15-19	No	Chibombo Hub
Chibombo	mwanjuni	10103701537	Male	32	Active	30	6/21/2024	Yes	Supressed	1	30-34	No	Chibombo Hub
Chibombo	mwanjuni	10012902251	Female	23	Active	0	7/18/2024	Yes	Supressed	1	20-24	No	Chibombo Hub
Chibombo	mwanjuni	10103700943	Female	28	Active	30	7/21/2024	Yes	Supressed	1	25-29	No	Chibombo Hub
Chibombo	mwanjuni	10103700838	Female	44	Active	0	1/12/2024	Yes	Supressed	1	40-44	No	Chibombo Hub
Chibombo	mwanjuni	10103701771	Female	30	Active	30	9/16/2024	Yes	Supressed	1	30-34	No	Chibombo Hub
Chibombo	mwanjuni	10103702300	Female	46	Active	30	2/8/2024	Yes	Supressed	1	45-49	No	Chibombo Hub
Chibombo	mwanjuni	TI-520	Female	50	Active	27	5/20/2024	Yes	Supressed	1	50+	No	Chibombo Hub
Chibombo	Mwanjuni	10012901556	Female	28	Active	30	11/15/2024	Yes	Supressed	1	25-29	No	Chibombo Hub
Chibombo	Mwanjuni	10012902377	Female	22	Active	0	6/20/2024	Yes	Supressed	1	20-24	No	Chibombo Hub
Chibombo	Mwanjuni	10103700307	Male	48	Active	30	8/24/2024	Yes	Supressed	1	45-49	No	Chibombo Hub
Chibombo	mwanjuni	TI-408	Female	28	Active	27	8/26/2024	Yes	Supressed	1	25-29	No	Chibombo Hub
Chibombo	mwanjuni	TI-451	Female	31	Active	27	10/11/2024	Yes	Supressed	1	30-34	No	Chibombo Hub
Chibombo	mwanjuni	TI-614	Female	33	Active	27	4/14/2024	Yes	Supressed	1	30-34	No	Chibombo Hub
Chibombo	mwanjuni	TI-059	Female	34	Active	27	5/5/2024	Yes	Supressed	1	30-34	No	Chibombo Hub
Chibombo	mwanjuni	10012902337	Female	26	Active	30	3/23/2024	Yes	Supressed	1	25-29	No	Chibombo Hub
Chibombo	mwanjuni	TI-617	Male	32	Active	27	8/21/2024	Yes	Supressed	1	30-34	No	Chibombo Hub
Chibombo	mwanjuni	TI-625	Female	79	Active	27	6/12/2024	Yes	Supressed	1	50+	No	Chibombo Hub
Chibombo	mwanjuni	TI-601	Female	27	Active	27	7/13/2024	Yes	Supressed	1	25-29	No	Chibombo Hub

6 months Adherence Call Tool

ADHERENCE FORM

Date ☐☐ / ☐☐ / ☐☐ (Day / Month / Year)

Patient ID ☐☐☐ - ☐☐☐ - ☐☐☐☐☐ - ☐ (District - Facility - Serial no.)

Patient Last Name _____ Patient First Name _____ Sex _____ Age ☐☐

Does the client have case manager/ treatment supporter? ◯ Yes ◯ No *Update treatment supporter information on HIV Summary Sheet*

Do you have any problem with the life of taking medication everyday: Yes No

PROBLEMS TAKING MEDICATION

Many clients taking these medications find it difficult from time to time. Does client ever have trouble taking the pills?
◯ Never ◯ Rarely ◯ Sometimes ◯ Often ◯ Very often

Since last visit, has client given any pills to another person?
Yes No How many pills given to another person?

How many doses has client missed in past 3 days? ☐

How many doses has client missed in the past 7 days?
☐ 0: regular pharmacy schedule
☐ 1: monthly call for 3 months
☐ 2 or more: Conduct in person visit within a month

REASONS FOR MISSED DOSES

REASON	ACTION
Forgot	Teach patient to use visual reminders or alarms
Side effects	Complete side effects section below
Felt too ill	Counsel on the importance of taking meds to feel better, refer to CO/MO
Away from home / travelling	Counsel patient on taking meds away from home
Attending a funeral	Counsel patient on taking meds away from home
Problems swallowing	Refer to CO/MO
Patient ran out of meds	Counsel on coming before meds finish, refer to pharmacy, use treatment supporter
Clinic ran out of meds	Alert ARV Nurse in Charge
Patient lost meds	Counsel patient on benefit of meds, consider using pill box
Did not want to take meds	Counsel patient on benefit of meds, consider referral to CO/MO
Too busy/disorganized	Counsel patient on benefit of meds, consider using pill box
Not enough food or money	Refer to appropriate organization, if available
Feels depressed	Refer to CO/MO
Feels well	Counsel patient on benefits of meds, emphasize lifelong treatment

Other_____

POSSIBLE SIDE EFFECTS

Has patient experienced any of the following signs or symptoms recently?

	REFER TO CLINICAL OFFICER/MEDICAL OFFICER IF:
Nausea	If causing minimal intake for more than 48 hours
Vomiting	If severe, limiting food or fluid intake or ART, and greater than 24 hours
Diarrhea	If more than 5 times per day, or bloody diarrhea, or if with fever or dehydration
Persistent headache	If severe, requiring frequent painkillers, lasting over 1 week
Rash	If severe, especially if associated with blisters, peeling or pain
Numbness/pain/burning in legs/feet	If new or worsening or impairs walking
Fever	If lasting more than one day
Difficulty breathing	Any difficulty, even if mild, especially if with abdominal pain, nausea or vomiting
Swelling	If new onset
Fatigue	If fatigue worsening since last visit
Severe abdominal pain	If it is too painful for the patient to move
Dizziness/lightheadedness	If persistent or worsening
Yellow eyes	If lasting more than one day
Other_____	

Comments_____

For patients on monthly adherence call follow up: this is visit number_____of 3 monthly discussions.

PAGE 1 OF 1 ADHERENCE v3.20.6_12MMD

12 MMD related Questions *(tick what is applicable)*

Sex: ☐ Male ☐ Female

Age: ☐ 16-19 ☐ 20-24 ☐ 25-29 ☐ 30-39 ☐ >40

Client Category: ☐ Migrant worker/Mobile Population
☐ Others Indicate: _____

Reasons for 12MMD:
What made you enroll for 12 MMD?
Tick all that apply

☐ To avoid frequenting the health facility
☐ To suit my business schedule
☐ To suit my work schedule
☐ To reduce the frequency of hospital permissions at work
☐ Others Indicate_____

Benefits of 12MMD:
What benefits have you observed with 12 MMD?
Tick all that apply.

☐ Cost saving
☐ Time saving
☐ Few work/business disruption
☐ Privacy and stigma reduction
☐ Others Indicate_____

Challenges of 12MMD:
What challenges did you experience with 12 MMD?
Tick all that apply

☐ Storage facility and safety at home
☐ The burden of carrying medicine bottles on the refill day
☐ Others Indicate_____

How has your experience been with 12 MMD?

Would you want to continue with 12 MMD?

Yes ☐
No ☐
Not sure ☐

Give reasons for your answer above:

12 MMD Enrolment distribution

- Enrolment Mean age 41 years
- Mode age group 35 to 39 years
- 64% enrolment were female
- 67% were from Central Province



6 months adherence call outcomes

Methodology:

- A total of 956 clients were contacted either by phone or through visits to offer adherence calls.
- Cross-sectional data was collected using an adherence call form and summarized quantitatively.



Retention in Treatment: after discounting for Trans-Out, 99% of clients on 12 MMD still Active on treatment

Sex	Patient Status				
	Active	Dead	LTFU (Missed 30> days)	Trans-outs (include silent transfer)	Total
Female	596	0	1	11	608
Male	360	1	3	2	366
Total	**956**	**1**	**4**	**13**	**974**

Crude Retention:*[Active/Total]* → **98%**

Pure Retention *[Active/(Total-Trans-out)]* → **99%**

VLC and VLS above 98%, 12 MMD clients at 12 months



icap Global Health

THE CQUIN NETWORK
cquin.icap.columbia.edu

Thank You!